GET DAILY SIGNALSBrainsWay (BWAY) Posts +34% Revenue Growth in Q3 2026 as Margins Expand
Key Takeaways
- BrainsWay reported third-quarter 2026 revenue of $18.1 million, up 34% from $13.5 million in the prior-year period.
- Gross margin expanded to 78%, up from 75% a year earlier, while operating income rose 107% to roughly $2.6 million.
- Adjusted EBITDA nearly doubled to $3.9 million, lifting the margin to 21% from 15%.
- The company shipped 130 Deep TMS systems, pushing its installed base above 2,000 devices, with remaining performance obligations up 31% to about $85 million.
- Management now expects full-year 2026 results to land at the upper end of prior guidance, with potential to modestly exceed those ranges.
Earnings Context and Why It Matters
BrainsWay stands out as a global leader in noninvasive neurostimulation treatments for mental health disorders through its proprietary Deep Transcranial Magnetic Stimulation platform. The third quarter provides a useful checkpoint on whether the company can translate its growing installed base into profitable, recurring revenue. With reimbursement coverage for the accelerated "SWIFT" protocol expanding quickly in the U.S., I am watching closely to see if demand and margins scale in tandem. Strong top-line growth alongside widening profitability would support the shift toward a more predictable, subscription-like model and bolster the case for operating leverage into 2027.
Reported Results
For the third quarter of 2026, BWAY reported revenue of $18.1 million, a 34% increase from $13.5 million in the same period last year and modestly above consensus estimates. Gross profit climbed 39% to $14.1 million, with gross margin reaching 78%. Operating income increased 107% to approximately $2.6 million, expanding operating margin to 14% of revenue from 9% a year ago.
Net income rose 42% to $2.2 million, though finance expenses tied to periodic loan valuation weighed on the bottom line. Adjusted EBITDA jumped 92% to $3.9 million. The company shipped 130 Deep TMS systems, up 44% year over year, and ended the quarter with remaining performance obligations of about $85 million, up 31%. Operating cash flow reached $6.2 million, and the cash position stood at roughly $63.4 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Reaction to the print was mixed. While revenue topped estimates, reported earnings per share came in below some consensus figures, and shares pulled back following the release. Investors appear to be weighing a modest bottom-line shortfall against a quarter where nearly every operating indicator improved, including margins, system shipments, backlog, and cash flow. The key tension remains whether accelerating expense growth, driven in part by one-time share-based compensation costs, will continue to outpace the strong top-line expansion. Sentiment stays supported by the swelling remaining performance obligations and the increasingly profitable, recurring revenue model.
Forward Outlook and Key Factors to Monitor
BWAY enters the final stretch of 2026 with raised visibility. Management indicated full-year results should reach the upper end of its existing guidance range, with the potential to modestly exceed it. The central question for investors is whether profitability can keep expanding as the company invests in commercial, clinical, and product development initiatives.
Several items are worth watching next. First, reimbursement trends remain the most important catalyst: coverage for the SWIFT accelerated protocol has surpassed 70 million covered lives in the U.S., and management noted that roughly half of new demand now involves the protocol. Further expansion of obsessive-compulsive disorder coverage and adolescent depression clearance could widen the addressable market.
Second, operating-expense discipline will be scrutinized after a quarter that included roughly $1 million in one-time items. Third, the company’s strategic investment program, including its minority stakes in mental-health clinic operators and its investment in home-based neuromodulation developer Neurolief, bears watching for how it influences future revenue and cash deployment. Finally, any regulatory updates on additional indications and the trajectory of book-to-bill orders will help confirm whether the current growth pace is sustainable into 2027.
Using Tickeron’s AI Tools for Deeper Analysis
In my own research process, I often turn to Tickeron’s AI Screener to quickly filter peers and spot comparable setups in the healthcare technology space. It helps surface patterns and fundamentals that complement traditional earnings analysis without replacing it. For anyone following names like BWAY, this kind of tool can surface additional context on volatility, trends, and relative performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BWAY in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 05, 2026
BWAY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 35 of 40 cases where BWAY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BWAY's RSI Indicator exited the oversold zone, 16 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 57 cases where BWAY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on BWAY as a result. In 81 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for BWAY just turned positive on October 19, 2026. Looking at past instances where BWAY's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.
Following a +9.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where BWAY advanced for three days, in 219 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BWAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for BWAY entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. BWAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 62 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 64 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.666) is normal, around the industry mean (4.142). P/E Ratio (44.600) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (8.681) is also within normal values, averaging (40.124).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer and manufacturer of deep transcranial magnetic stimluation systems, novel, noninvasive medical devices
Industry MedicalNursingServices
Advertisement